The Enhanced Liver Fibrosis (ELF™) Test is a simple solution to this complex problem with the power to improve outcomes for millions of advanced NASH patients.
Easy to obtain, administer, and interpret, the ELF Test is a routine blood test proven to predict progression to cirrhosis and liver related events in patients with NASH with advanced fibrosis (F3 or F4).3 Enabling accessible, effortless testing, the ELF Test simplifies and accelerates the identification of NASH patients with advanced fibrosis who may benefit most from potentially life-saving preemptive care; an important first-step in turning the tide against the liver’s silent killer.
- Access noninvasive testing with a simple blood test available to all patients, including those with type 2 diabetes mellitus and obesity.1,2
- Improve patient care by stratifying advanced NASH patients most at risk of progressing to cirrhosis and LREs.3
- Enhance patient management with a blood test that facilitates more frequent prognostic assessments.
Webinar: The ELF Test & Unmet Challenges of Growing NASH Epidemic
Learn more about the Enhanced Liver Fibrosis (ELFTM) Test, the first blood test to be granted De Novo Marketing Authorization by the FDA for prognosis in advanced fibrosis due to NASH. Speaker H. Roma Levy, MS., discusses how the ELF Test can address the unmet needs in prognostic evaluation of NASH.
This Webinar was recorded live on Wednesday, October 27th but is available to watch on demand here.
The Enhanced Liver Fibrosis (ELF™) Test is a noninvasive blood test that quantifies three analytes which directly contribute to liver fibrosis. ELF measurements have proven valuable for identifying patients with NASH with advanced fibrosis (F3 or F4) at risk of progressing to cirrhosis and/or LREs.
The widely studied ELF Test can assess active, dynamic fibrosis rather than the damage it has caused. This allows the ELF Test to be used as a prognostic marker.
Interpretation of Results
Interpret the ELF score using the following guidelines:
Risk of Disease Progression (Development of Cirrhosis or Liver-Related Events)
≥ 9.80 - < 11.30
* In the Mid group, the risk of disease progression is similar to the pre-test risk. Pre-test risk refers to the likelihood of disease progression in the overall intended use population without considering the ELF score.
Results should always be interpreted in conjunction with the patient's medical history, clinical presentation, and other findings.
Did this information help you?
Patel P, et al. Hepatol Commun. 2018;2:893-905.
Karlas T, et al. PLoS ONE. 2015;10(11):e0141649.
Sanyal AJ, et al. Hepatology. 2019 Apr 16. doi: 10.1002/hep.30664. [Epub ahead of print].